MindImmune Backed by Alzheimer’s Drug Discovery Foundation to Advance First-in-Human Trials
Slater Technology Fund portfolio company MindImmune has received backing from the Alzheimer’s Drug Discovery Foundation (ADDF), supporting the company’s advancement into first-in-human trials.
For MindImmune, this 2nd A3 close builds on the $10.2m back in November (2025) and is a meaningful external validation from one of the most important organizations in Alzheimer’s research and drug development. For Slater, it marks the continued progress of a company the firm has supported since 2016, joining shortly after its initial financing and remaining invested through nearly a decade of scientific and clinical advancement.
MindImmune began in the George & Anne Ryan Institute for Neuroscience, with CNS drug-discovery scientists and longtime collaborators Stevin Zorn, Ph.D., Frank Menniti, Ph.D., and Robert Nelson, Ph.D. leading the company from its earliest stages. Since then, the team has worked to translate foundational neuroscience into a therapeutic approach targeting neuroinflammation, an area of growing importance in neurodegenerative disease.
This latest support from ADDF represents a major step forward for the company and a significant milestone on the path from academic research to clinical development.